DSIP (Delta Sleep-Inducing Peptide): Mechanism, Literature, and Verification

Few research peptides carry a name as evocative — or as misleading — as delta sleep-inducing peptide. DSIP was isolated in the late 1970s from the cerebral venous blood of rabbits during an electrically induced sleep state, and it was christened for the delta-wave EEG activity that accompanied its discovery. Nearly five decades later, the peptide remains one of neuroscience’s more durable open questions: an endogenous nonapeptide with a well-defined sequence, a broad and reproducible set of preclinical effects, and no single, universally agreed receptor. For a laboratory assembling a reference library around neuropeptide signaling, stress-response biology, or antioxidant-defense pathways, DSIP is a compact, historically important, and unusually well-studied tool compound. This guide surveys it strictly at the molecular and preclinical level: what it is, how it is thought to act at the pathway level, what the primary literature actually reports, and how a research group should evaluate the material it sources.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes.

Section 1 — Molecular Profile

Delta sleep-inducing peptide is a small, linear nonapeptide — nine amino acids, no disulfide bridges, no terminal modifications in its native form. That structural simplicity is part of why it became a standard research tool: it is straightforward to synthesize, characterize, and handle, and it presents a clean, unmodified baseline against which chemically stabilized analogs can be compared.

Delta sleep-inducing peptide (DSIP)
– CAS number: 62568-57-4
– Molecular formula: C35H48N10O15
– Molecular weight: approximately 848.8 g/mol (849 Da)
– Length: 9 amino acids
– Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)
– Class: endogenous neuropeptide; sleep- and stress-related signaling factor

DSIP was first described by Monnier, Schoenenberger, and colleagues, who identified a dialyzable factor in the venous cerebral blood of rabbits undergoing electrically induced synchronized sleep and, over subsequent years, purified and sequenced it to the nonapeptide above. The molecule is amphoteric, water-soluble, and notably labile: unmodified DSIP is rapidly degraded by plasma and tissue peptidases, and its measured half-life in the presence of serum enzymes is short. That instability is itself a research-relevant property — it is the reason a family of more resistant analogs (for example, the phosphorylated derivative and various N- and C-terminally modified sequences) was engineered as more durable comparators, with unmodified DSIP serving as the reference sequence. Reported preparations are typically supplied as a lyophilized acetate salt for reconstitution in aqueous buffer.

Section 2 — Mechanism

DSIP is best discussed at the pathway level, and honesty about its limits is part of describing it accurately: despite decades of study, no single high-affinity DSIP receptor has been definitively cloned and universally accepted. This is one of the genuinely unresolved features of the molecule, and any rigorous research framing has to state it plainly rather than assert a receptor that the literature has not settled. What the preclinical record does describe is a set of reproducible, pathway-level interactions in model systems.

The first is neuromodulatory. In electrophysiological and brain-slice work, DSIP has been associated with modulation of delta-frequency (slow-wave) EEG activity and with effects on both GABAergic and glutamatergic tone. One of the more mechanistically concrete observations is anticonvulsant activity in rodent models, where DSIP raised the threshold to NMDA-receptor- and picrotoxin-induced seizure activity — implicating excitatory-inhibitory balance rather than a single dedicated “sleep receptor.” A second, independently characterized axis is neuroendocrine: DSIP has been reported to interact with hypothalamic-pituitary-adrenal signaling and with the release of several pituitary factors, positioning it within stress-response circuitry.

The most reproducible mechanistic theme in the modern literature, however, is antioxidant and cytoprotective. Across rodent tissue studies, DSIP has been shown to suppress lipid peroxidation — measured as reduced malondialdehyde accumulation — and to raise the activity and gene expression of endogenous antioxidant enzymes, including superoxide dismutase (SOD), catalase, and glutathione peroxidase. This is a pathway-level effect on the cell’s own redox-defense machinery rather than a direct free-radical-scavenging action, and it is the mechanistic thread that connects the peptide’s reported neuroprotective, anti-stress, and geroprotective observations in preclinical models. DSIP and several analogs have also been reported to cross the blood-brain barrier in animal models, a property relevant to its central activity. Everything in this article is framed at exactly this level: EEG modulation, excitatory-inhibitory balance, neuroendocrine interaction, and induction of endogenous antioxidant-enzyme systems in cell and tissue models.

Section 3 — Preclinical Research Data

The DSIP literature spans an unusually long window — from its 1970s isolation to active studies published in the 2020s — and the through-line is a peptide that produces broad cytoprotective effects in stress and injury models. The foundational work was the isolation and sequencing itself: the demonstration that a discrete, dialyzable nonapeptide could be recovered from sleep-state cerebral blood and chemically defined established DSIP as a candidate endogenous signaling factor and set the agenda for everything that followed. Early reviews catalogued a striking breadth of reported activities — effects on sleep architecture, on thermoregulation, on stress hormones, and on tolerance to a range of noxious stimuli.

The modern preclinical record has concentrated on the antioxidant and neuroprotective axis. A frequently cited 2021 study in Molecules by Tukhovskaya and colleagues reported that DSIP administration improved motor-function recovery in a rat model of focal ischemic stroke, with the recovery associated with the peptide’s antioxidant and cytoprotective activity in nervous tissue. This built on an earlier body of Russian and international work showing that DSIP pretreatment blunted the biochemical markers of oxidative stress in rodent tissues — reducing lipid-peroxidation products while elevating SOD, catalase, and ceruloplasmin activity — and that it protected mitochondrial respiratory function against hypoxic challenge in isolated tissue.

A separate line of aging-model research examined DSIP’s effect on the transcription of antioxidant-enzyme genes in the brain and blood of aging rats, reporting increased expression of the genes encoding SOD and glutathione peroxidase. This gene-expression finding is what underlies the peptide’s characterization in the geroprotective literature: the proposed mechanism is not that DSIP directly quenches radicals, but that it up-regulates the cell’s own antioxidant-defense program. Across these datasets the consistent observation is that DSIP behaves as a broad stress-buffering and redox-modulating agent in preclinical models — which is precisely why it remains a useful probe for studying endogenous antioxidant-enzyme regulation in vitro.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for a DSIP research library:

• Schoenenberger GA, Monnier M. “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.” Proceedings of the National Academy of Sciences USA, 1977; 74(3):1282-1286.
• Graf MV, Kastin AJ. “Delta-sleep-inducing peptide (DSIP): a review.” Neuroscience & Biobehavioral Reviews, 1984; 8(1):83-93.
• Kovalzon VM, Strekalova TV. “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” Journal of Neurochemistry, 2006; 97(2):303-309.
• Sudakov KV, Umriukhin PE, Rayevsky KS. “Delta-sleep inducing peptide and neuronal activity after glutamate microiontophoresis: the role of NMDA-receptors.” Pathophysiology, 2004; 11(2):81-86.
• Khvatova EM, Samartzev VN, Zagoskin PP, et al. “Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia.” Peptides, 2003; 24(2):307-311.
• Bondarenko TI, Mikhaleva II, Ryzhak GA, et al. “Effect of delta sleep-inducing peptide on the expression of antioxidant enzyme genes in the brain and blood of rats during physiological aging.” Bulletin of Experimental Biology and Medicine, 2014; 157(5):604-607.
• Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. “Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke.” Molecules, 2021; 26(17):5173.

These references trace DSIP from its original isolation and sequencing, through the classic reviews that catalogued its breadth of preclinical activity, to the modern receptor-pharmacology and antioxidant-enzyme work that defines the mechanistic questions still open today — the primary literature a research group needs to design and interpret in-vitro work on the peptide.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, DSIP is studied for a set of overlapping, model-system purposes:

• Antioxidant-defense signaling: as a probe for how a peptide up-regulates endogenous antioxidant-enzyme systems (SOD, catalase, glutathione peroxidase) at the activity and gene-expression level in cell and tissue models.
• Oxidative-stress and hypoxia models: measuring lipid-peroxidation markers (malondialdehyde) and mitochondrial respiratory activity in tissue preparations subjected to hypoxic or ischemic challenge.
• Neuromodulation and excitatory-inhibitory balance: electrophysiological and brain-slice work on delta-frequency activity and on GABAergic/glutamatergic and NMDA-threshold effects.
• Neuroendocrine and stress-axis studies: characterizing DSIP’s reported interactions with hypothalamic-pituitary signaling as a model of peptide-mediated stress buffering.
• Structure-activity and stability studies: using unmodified DSIP as the labile reference sequence against which peptidase-resistant analogs are compared for half-life and activity.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade DSIP is supplied as a research chemical rather than a finished pharmaceutical preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage figure — important for a short peptide where truncated and deletion sequences are common synthesis impurities.
• LC-MS or MS identity confirmation of the ~849 Da target mass, which distinguishes genuine full-length DSIP from shorter fragments or a mis-synthesized sequence.
• Endotoxin and heavy-metal testing for lyophilized material intended for cell-based work, since bacterial endotoxin independently activates stress and inflammatory pathways and confounds redox and neuromodulation assay readouts.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, DSIP generally trades at a moderate price point — commonly around $50–$60 for a 5 mg lyophilized vial across research-chemical suppliers, roughly $10–$12 per milligram — because its nine-residue length makes it comparatively simple to synthesize. That accessibility cuts both ways: it lowers the barrier to sourcing, but it also means a poorly characterized product carrying deletion sequences can look superficially attractive. Price alone says nothing about identity or purity; only third-party analytical data does. Given that DSIP is chemically labile, batch handling and documented purity matter more here than for a more robust peptide, not less.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a peptide like DSIP, orthogonal identity testing is what separates a genuine nonapeptide from a mislabeled or truncated fragment. Because the compound is labile and its activity in the literature is tied to the intact WAGGDASGE sequence, LC-MS confirmation of the ~849 Da target mass — not just a purity percentage — is the only way to verify that a vial contains full-length DSIP rather than a deletion sequence or degradation product. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/dsip/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.